| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding | |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | Entrez:930 MIM:107265 HGNC:HGNC:1633 Ensembl:ENSG00000177455 AllianceGenome:HGNC:1633 | |
| Description | CD19 molecule | |||||
| GTO ID | GTC0714 |
| Trial ID | ACTRN12619001656123 |
| Disease | Non-Hodgkin's Lymphoma |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CD19 CAR-T cells |
| Phase | Phase1 |
| Recruitment status | Not Recruiting |
| Title | A study to see how feasible it is to deliver Chimeric antigen receptor (CAR) T cells to patients diagnosed early with Primary refractory and early relapsed diffuse large B cell lymphoma. |
| Year | 2019 |
| Country | Australia |
| Company sponsor | Australasian Leukaemia and Lymphoma Group |
| Cohort 1 | |||||||||||
|
|||||||||||